Cara Therapeutics | CARA - Cash And Equivalent


Cara Therapeutics reported $19.85M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 956.47M 105.02M Jun/2026
Alterity Therapeutics Limited AUD 15.77M 9.56M Jun/2023
Cara Therapeutics USD 19.85M 883K Mar/2026
Cassava Sciences USD 86.57M 8.93M Mar/2026
Chugai Pharma JPY 426.6B 29.83B Dec/2025
Cipla INR 10.18B 2.22B Mar/2026
Clal Biotechnology ILS 5.73M 1.71M Dec/2023
Compugen USD 12.43M 78.16M Mar/2026
CSL USD 2.16B 633M Jun/2025
Grifols EUR 979.78M 334.84M Dec/2024
Halozyme Therapeutics USD 163.14M 146.61M Jun/2026
J&J USD 20.42B 1.27B Jun/2026
Neurocrine Biosciences USD 332.4M 65.9M Jun/2026
Pacira USD 205.88M 61.57M Jun/2026
Pfizer USD 976M 727M Jun/2026
RedHill Biopharma USD 2.87M 1.75M Jun/2025
Supernus Pharmaceuticals USD 179.95M 4.92M Jun/2026
Vanda Pharmaceuticals USD 84.85M 14.83M Dec/2025